Spruce Biosciences Inc. (SPRB): Price and Financial Metrics
SPRB Price/Volume Stats
| Current price | $1.48 | 52-week high | $3.57 |
| Prev. close | $1.40 | 52-week low | $0.95 |
| Day low | $1.44 | Volume | 46,558 |
| Day high | $1.51 | Avg. volume | 503,718 |
| 50-day MA | $1.49 | Dividend yield | N/A |
| 200-day MA | $2.06 | Market Cap | 60.25M |
SPRB Stock Price Chart Interactive Chart >
SPRB POWR Grades
- SPRB scores best on the Sentiment dimension, with a Sentiment rank ahead of 98.25% of US stocks.
- SPRB's strongest trending metric is Quality; it's been moving up over the last 177 days.
- SPRB ranks lowest in Momentum; there it ranks in the 19th percentile.
SPRB Stock Summary
- With a price/sales ratio of 10.35, SPRUCE BIOSCIENCES INC has a higher such ratio than 91.15% of stocks in our set.
- Revenue growth over the past 12 months for SPRUCE BIOSCIENCES INC comes in at 110.23%, a number that bests 95.65% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SPRB comes in at -123.85% -- higher than that of merely 4.93% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to SPRUCE BIOSCIENCES INC, a group of peers worth examining would be STTK, PIRS, ABUS, SYBX, and IKNA.
- SPRB's SEC filings can be seen here. And to visit SPRUCE BIOSCIENCES INC's official web site, go to www.sprucebiosciences.com.
SPRB Valuation Summary
- In comparison to the median Healthcare stock, SPRB's price/sales ratio is 200% higher, now standing at 10.8.
- Over the past 37 months, SPRB's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for SPRB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SPRB | 2023-11-03 | 10.8 | 0.5 | -0.9 | 1 |
| SPRB | 2023-11-02 | 11.0 | 0.5 | -0.9 | 1 |
| SPRB | 2023-11-01 | 11.0 | 0.5 | -0.9 | 1 |
| SPRB | 2023-10-31 | 11.2 | 0.5 | -1.0 | 1 |
| SPRB | 2023-10-30 | 11.0 | 0.5 | -0.9 | 1 |
| SPRB | 2023-10-27 | 10.2 | 0.4 | -0.9 | 1 |
SPRB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SPRB has a Quality Grade of D, ranking ahead of 21.49% of graded US stocks.
- SPRB's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows SPRB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | NA | -2.147 |
| 2020-12-31 | 0 | NA | -20.921 |
SPRB Price Target
For more insight on analysts targets of SPRB, see our SPRB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.20 | Average Broker Recommendation | 1.4 (Strong Buy) |
Spruce Biosciences Inc. (SPRB) Company Bio
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.
Latest SPRB News From Around the Web
Below are the latest news stories about SPRUCE BIOSCIENCES INC that investors may wish to consider to help them evaluate SPRB as an investment opportunity.
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif., November 13, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates. |
Spruce Biosciences to Participate in the Jefferies London Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., November 02, 2023--Spruce Biosciences to Participate in the Jefferies London Healthcare Conference |
Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal HyperplasiaSOUTH SAN FRANCISCO, Calif., October 18, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced completion of target enrollment of 72 patients and closure of screening in the CAHmelia-203 clinical trial evaluating tildacerfont for the treatment of adult classic congenital adrenal hyperplasia (CAH) and provided updated anticipat |
Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSOUTH SAN FRANCISCO, Calif., August 28, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023, at 3:30 p.m. ET. |
Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesSOUTH SAN FRANCISCO, Calif., August 14, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. |
SPRB Price Returns
| 1-mo | 32.14% |
| 3-mo | -33.63% |
| 6-mo | -36.62% |
| 1-year | 29.82% |
| 3-year | -94.99% |
| 5-year | N/A |
| YTD | 34.86% |
| 2022 | -75.39% |
| 2021 | -81.65% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...